KARACHI: The Center for Bioequivalence Studies and Clinical Research (CBSCR) at the Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD), University of Karachi, has signed a Mutual Confidentiality and Nondisclosure Agreement (NDA) with Minerva Research Solutions to strengthen cooperation in clinical trials and bioequivalence studies.
A spokesperson for the International Center for Chemical and Biological Sciences (ICCBS) said the agreement aims to promote collaboration in key areas of pharmaceutical and biomedical research. The signing ceremony took place at the HEJ Research Institute of Chemistry, where Prof. Dr. Muhammad Raza Shah, Director ICCBS, and Dr. Ashfaq Ahmed, Director Business Development & Operations at Minerva Research Solutions, formalized the partnership.
Prof. Dr. Muhammad Raza Shah stated that the CBSCR, a leading research component of the Dr. Panjwani Center, is now fully operational and has successfully completed bioequivalence and pharmacokinetic studies in line with national and international standards. He added that the facility also includes Pakistan’s first clinical trial unit capable of conducting studies in accordance with global regulatory requirements.
He termed the NDA an important step toward strengthening academic–industry collaboration to advance innovation in pharmaceutical and biomedical sciences.
Dr. Ashfaq Ahmed said Minerva Research Solutions expects the partnership to deepen scientific engagement based on transparency, intellectual property protection, and mutual trust.
The agreement will remain valid for three years, with confidentiality obligations continuing beyond the contract period to ensure long-term protection of proprietary data and research information.
